Stroke Prevention in Sickle Cell Anemia (STOP 1)


Phase 3 Results


Interim analysis showed a 92% decrease (P < 0.001) in the transfusion-treated childrens' relative risk of stroke: after one year, 10 children in the standard-care group (N = 67) had experienced a cerebral infarction, compared with only one child from the transfusion group (N = 63). These results led to the early termination of the trial.